Quick Answer
CytoDyn Inc. reported R&D Expense of $7.24 million for fiscal year 2024.
CytoDyn Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $7.24M | +175.1% |
| 2023 | $2.63M | -90.3% |
| 2022 | $27.04M | -49.4% |
| 2021 | $53.40M | +1.4% |
| 2020 | $52.64M | +23.9% |
| 2019 | $42.49M | +11.2% |
| 2018 | $38.22M | +89.2% |
| 2017 | $20.21M | +47.1% |
| 2016 | $13.73M | -9.4% |
| 2015 | $15.16M | +280.7% |
| 2014 | $3.98M | +542.3% |
| 2013 | $619.8K | +16.9% |
| 2012 | $530.0K | +10.2% |
| 2011 | $480.8K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| February 29, 2024 | $650.0K | -30.7% | -39.8% |
| November 30, 2023 | $1.08M | +687.6% | -43.6% |
| August 31, 2023 | $1.91M | +232.3% | +104.1% |
| February 28, 2023 | $938.0K | -73.7% | +584.7% |
| November 30, 2022 | $137.0K | -98.2% | -76.2% |
| August 31, 2022 | $576.0K | -95.2% | -83.9% |
| February 28, 2022 | $3.57M | -71.0% | -52.1% |
| November 30, 2021 | $7.45M | -54.7% | -38.0% |
- CytoDyn Inc. showed an increase of +175.1% in R&D Expense compared to the prior fiscal year.
- Over the 2011–2024 period, CytoDyn Inc.’s r&d expense has grown by 1405.9% (from $480.8 thousand to $7.24 million).
- The most recent figure is from CytoDyn Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on August 15, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: